Full text is available at the source.
Abstract
Adults with Type 2 diabetes initiating semaglutide, tirzepatide, or sodium-glucose cotransporter-2 inhibitors may have differing risks of developing alcohol use disorder.
- The study aims to assess the incidence of alcohol use disorder among adults with Type 2 diabetes.
- Three treatment options are being compared: semaglutide, tirzepatide, and sodium-glucose cotransporter-2 inhibitors.
- Understanding these risks could provide insights into the safety profiles of these medications for individuals with Type 2 diabetes.
Simplified